Aprea Therapeutics

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Boston, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

Wedbush analyst Robert Driscoll just gave a huge upside target for APRE stock. Here's why this is significant for the biotech sector.

Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals' drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA.

Karolinska Development's portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022.

Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months and year ended December 31, 2021 and provided a business update.

Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced updated results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML at the 2021 ASH Annual Meeting.

Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting

Arbutus Biopharma

Remark Hlds

Meten Holding Group Ltd.

Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?

Got $5 to Spend on Penny Stocks? Check These 4 Out

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

The FDA removed the full clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. The agency issued a clinical hold on the study in August.

FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies

The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) increased by over 14% during intraday trading today. This is why it happened.

Aprea Therapeutics Stock (APRE): Why The Price Increased Today

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and nine months ended September 30, 2021 and provided a business update.

Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that investigators will present data from clinical trials evaluating eprenetapopt at the 63rd American Society of Hematology Annual Meeting (ASH).

Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting

Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors.  The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab.

Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase I/II clinical trial in advanced solid tumors. The trial is evaluating the safety and efficacy of eprenetapopt in combination with pembrolizumab.

Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021

Investors need to pay close attention to Aprea Therapeutics (APRE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?

The stock price of Aprea Therapeutics Inc (NASDAQ: APRE) is trading higher today. This is why it happened.

APRE Stock: Why It Increased Today

Capricor Therapeutics

ConforMIS

Spectrum Pharma

Verastem

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and six months ended June 30, 2021 and provided a business update.

Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations

After instituting a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) myeloid malignancies program, the FDA has placed a clinical hold on Aprea's lymphoid malignancy study.  The trial is evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies.

Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its clinical trial evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. No additional patients can be enrolled until the clinical hold is resolved, though patients on study deriving clinical benefit can continue to receive study treatment.

Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) clinical trials of eprenetapopt (APR-246) combined with azacitidine in its myeloid malignancy programs.  Approximately 20 patients currently receiving eprenetapopt in combination with azacitidine in the Company's myeloid malignancy programs, including the MDS, AML, and post-transplant maintenance trials, all of which have completed enrollment.

Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial.

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

Aprea Therapeutics Inc (NASDAQ: APRE) has announced results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In 33 patients enrolled in the trial, the relapse-free survival (RFS) at 1-year post-transplant was 58%, and the median RFS was 12.1 months.

Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Transplant

Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.

News for Aprea Therapeutics Stock (APRE)